Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening Test
26 sept. 2023 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that the Dubai government has officially approved insurance reimbursement for the EZ...
Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors
28 août 2023 08h19 HE
|
Biomerica, Inc.
Kenny has proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian...
Biomerica Reports Fiscal 2023 Year End Results
25 août 2023 17h00 HE
|
Biomerica, Inc.
Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed inFoods® IBS pilot program with one of the largest Gastrointestinal physician groups in the US ...
CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Disease Screening Test
03 août 2023 08h19 HE
|
Biomerica, Inc.
Over 7,000 CVS Pharmacy Stores to sell the EZ Detect™ TestSimple 2 minute at-home test detects an early warning sign of colorectal cancer IRVINE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) --...
Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients
21 juin 2023 08h19 HE
|
Biomerica, Inc.
Patent Claims Describe a Novel System to Predict and Help Prevent Adverse Food Reactions Using Personal Medical DataThe Patent further describes Algorithms to help Determine Safety Levels of Food...
inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology
18 mai 2023 08h19 HE
|
Biomerica, Inc.
Gastro Health, a leading gastroenterology group, plans to utilize this simplified blood collection method when recommending the inFoods® IBS to their patients Biomerica also announced that inFoods®...
Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
17 avr. 2023 07h47 HE
|
Biomerica, Inc.
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United StatesClinical study results show patients who eliminated foods as determined by the inFoods® IBS test...
Biomerica Reports Q3 Fiscal 2023 Results
14 avr. 2023 16h48 HE
|
Biomerica, Inc.
For the nine months ended February 28, 2023 vs. the same period in 2022, revenues, excluding sales of Covid-related products, increased by 16%.InFoods® IBS Laboratory Developed Test (LDT) validation...
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed
08 mars 2023 08h19 HE
|
Biomerica, Inc.
InFoods® IBS LDT validation testing at the CLIA Lab is completed and the product is now being offered commerciallyClinical trial data shows InFoods® IBS treatment diet significantly improved several...
Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock
07 mars 2023 16h39 HE
|
Biomerica, Inc.
IRVINE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today the closing of its previously...